Background--Acute kidney injury (AKI) and dialysis-requiring AKI (AKI-D) are common, serious complications of cardiac procedures.
P
ercutaneous coronary intervention (PCI) and other types of cardiac catheterization (e.g., diagnostic procedures of the heart) are increasingly prevalent in the United States, accounting for over 2 000 000 procedures annually. 1, 2 This increase has been driven by the substitution of cardiac surgeries for less-invasive catheterization, increased hospital catheterization capacity, and a greater emphasis on evidencebased care for noncomplex lesions. [2] [3] [4] [5] One of the most common complications of cardiac catheterization and PCI is acute kidney injury (AKI). Cardiac catheterization or PCI patients who develop AKI have an increased risk of cardiovascular events, end-stage renal disease, all-cause mortality, increased length of stay, and additional acute care costs of $7500. [6] [7] [8] AKI severity is positively associated with morbidity and mortality, and dialysis-requiring AKI (AKI-D) is associated with the highest rates of morbidity and mortality among patients with post-procedural AKI. 9, 10 The primary cause of AKI and AKI-D in cardiac catheterization or PCI patients is the use of nephrotoxic, iodinated contrast media for cardiac imaging. Contrast-induced AKI occurs in 3% to 14% of cardiac catheterization or PCI patients and is the third-most common cause of AKI in hospitalized patients. [11] [12] [13] The 2 primary mechanisms by which contrast media can cause nephrotoxicity are vasoconstriction/ischemic injury and direct toxicity to renal tubular cells. 14 These pathways lead to acute tubular necrosis and renal cell apoptosis, causing renal dysfunction. Because of increased use and complexity of cardiac catheterization and PCI requiring large volumes of contrast media, we hypothesized that incidence of AKI and AKI-D has increased among patients undergoing these procedures. Using a nationally representative sample and census data, we calculated the population-based incidence and associated in-hospital mortality of AKI and AKI-D among cardiac catheterization or PCI patients in the United States from 2001 to 2011.
Methods
We used National Inpatient Sample (NIS) discharge data from 2001 to 2011. The NIS is a yearly nationally-representative, stratified sample of 20% of community-based hospitals in the United States, making it the largest US all-payer inpatient database available to researchers. 15 Thirty-three states (986 hospitals) contributed over 7 400 000 discharge records to this database in 2001. The NIS grew to 46 states, 1049 hospitals, and over 8 000 000 discharge records by 2011. The Committee for the Protection of Human Subjects at Dartmouth College waived required approval for this study because the NIS contains no protected health information and is publicly available. Our study cohort consisted of hospitalizations requiring PCI or cardiac catheterization during the study period. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure and diagnosis codes were used to identify and describe these patients. We defined PCI or cardiac catheterization cases using any of the following ICD-9-CM codes: 0066 (percutaneous transluminal coronary angioplasty); 3601 to 3609 (operations on vessels of heart); 3722 to 3723 (diagnostic procedures on heart and pericardium); or 8853 to 8857 (angiocardiography using contrast material).
Primary outcomes were occurrence of AKI and AKI-D and in-hospital mortality postcardiac catheterization or PCI. Cases of AKI were identified using the following ICD-9-CM codes for acute renal failure: 584.5 (with tubular necrosis); 584.6 (with lesion of renal cortical necrosis); 584.7 (with lesion of renal medullary necrosis); 584.8 (other specified pathological lesion in kidney); or 584.9 (unspecified). Cases of AKI-D were defined as an AKI diagnosis plus a co-listed code for hemodialysis, hemofiltration, or peritoneal dialysis (V45.1, V56.0, 39.95, V56.1, and 54.98). Records with hemodialysis, hemofiltration, or peritoneal dialysis procedure codes without an AKI diagnosis code were excluded from the analysis, as in similar investigations. 16 Patients with arteriovenous fistula creation or revision procedure codes (39.27, 39.42, 39.43, and 39.93) were excluded from analysis to increase sensitivity and specificity for acute dialysis procedures. 17 In our model, we accounted for co-occurring conditions, age, sex, cardiac procedure characteristics, and hospital utilization practices in adjusted analyses (we hypothesized no difference in sex). NIS comorbidity indicators were used to identify these co-occurring conditions (congestive heart failure, pulmonary circulation disorders, peripheral vascular disease, hypertension, other neurological disorders, chronic pulmonary disease, diabetes without chronic complications, diabetes with chronic complications, renal failure, obesity, fluid and electrolyte disorders, blood loss anemia, and deficiency anemias). Specific ICD-9-CM codes used to identify co-occurring conditions are available for review. 18 For adjustment for cardiac procedure characteristics, we also identified sepsis cases (038.x, 112.5, 112.81, 020.2, 790.7, and 785.59) and the number of stents placed during angioplasty, which was considered to account for coronary vessel disease severity and procedure intensity (0045-0048). Lastly, our model was adjusted for yearly median length of stay and the proportion of patients discharged to skilled nursing facilities. We adjusted for discharge to skilled nursing facilities and median lengths of stay to account for potential changes in discharge practices over time and/or between hospitals. This model applies to both AKI and AKI-D. These measures may be an indicator of unmeasured confounding attributed to unmeasured comorbidities. Additionally, length of stay has declined over time, and discharge to skilled nursing facilities has been shown to increase over time. 19 We calculated the population incidence of AKI and AKI-D for patients who underwent cardiac catheterization or PCI in the United States from 2001 to 2011 by dividing the unweighted number of discharges with AKI or AKI-D by the annual US population (according to the U.S. Census Bureau). 17 Incidence estimates were stratified by sex and age for subgroup analysis. We then used multiple logistic regression to determine the odds of AKI, AKI-D, and corresponding in-hospital mortality. To account for the sampling frame and clustering, we applied population weights to the model. Crude and adjusted models were used to estimate the odds of AKI and AKI-D per a 1-year increase. We performed the same analysis for sex and age subgroups. Because the NIS has been adding data from more and more states over the years, including during our study period, we adjusted for covariates over time to counteract the addition of these states. We used crude and adjusted models to estimate the odds of mortality for each year, with 2001 as a reference. Adjusted models accounted for age, sex, race, congestive Table 1 . (1) 1506 (0) 1247 (0) 1173 (0) 1803 (1) 2571 (1) 1609 (0) 1485 (0) 1381 (0) 1231 (0) 1352 (1) 1414 (1) 20 to 44 247 659 (7) 24 094 (7) 25 752 (7) 27 310 (7)
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Results
Yearly characteristics for cardiac catheterization and PCI patients are displayed in Table 1 . Sample sizes are unweighted, whereas percentages are population-weighted. The proportion of patients undergoing only cardiac catheterization remained stable (56.9-56.0%), whereas the proportion of patients undergoing only PCI decreased (6. Figure 1 ). However, the AKI incidence among cardiac catheterization or PCI patients did not increase uniformly every year. AKI incidence declined substantially in 2010. AKI-D incidence had similar patterns of overall growth and decline in 2010 (Figure 2 ). Unadjusted logistic regression showed that patients had 1.17 (95% CI, 1.16-1.18) times the odds of AKI per 1-year increase (Table 2) . After adjustment for patient, cardiac procedure, and hospital characteristics, the odds of developing AKI were 1.11 times the previous year (95% CI, 1.10-1.12). AKI incidence increased similarly for men Table 1 . (10) 35 435 (11) 40 923 (13) 42 261 (14) 39 477 (15) 46 614 (17) Chronic blood loss anemia 23 134 (1) 0 (0) 2236 (1) 2472 (1) 2498 (1) 2656 (1) 2792 (1) 2581 (1) 2309 (1) 2156 (1) 1642 (1) 1792 (1) Deficiency anemias 297 657 (8) 2 (0) 22 992 (6) 24 541 (7) 24 255 (7) 24 645 (7) 28 491 (8) (1) 3186 (1) 3778 (1) 3941 (1) 3889 (1) 4288 (1) 4786 (1) 4785 (2) 5551 (2) 5960 (2) 5503 (2) 6358 (2) SNF or ICF 212 729 (6) 18 093 (5) 18 844 (5) 19 396 (5) 19 180 (6) 18 814 (6) 20 020 (5) 18 920 (6) 20 672 (6) 20 357 (7) 18 410 (7) 20 023 (8) Died 60 354 (2) 6205 (2) 6136 (2) 6217 (2) 5384 (2) 5155 (2) 5417 (2) 4934 (2) 5468 (2) 5347 (2) 4805 (2) 5286 (2) Please note that sample sizes are unweighted, but percentages are population-weighted. CHF indicates congestive heart failure; ICF, intermediate care facility; PCI, percutaneous coronary intervention; SNF, skilled nursing facility.
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Journal of the American Heart Association and women over the study period. However, the increase in AKI incidence for men outpaced that of women ( Figure 3 ). Across age groups, AKI incidence increased similarly, except for the 0 to 19 and 20 to 40 age groups, in which AKI incidence plateaued toward the study period's end (Figure 4) . Table 4 ). However, this increase was masked by an even larger yearly increase in total AKI incidence after cardiac catheterization or PCI. The population-attributable risk of mortality associated with developing AKI after cardiac catheterization or PCI was 25.8% in 2001 compared to 41.1% in 2011 (Table 4) .
Because discharges to skilled nursing facilities remained static over the study period, it is unlikely that variability in hospital characteristics impacted mortality estimates. Length of stay decreased among AKI patients in the study period Figure 1 ). At-risk patients had 1.11 (95% CI, 1.09-1.13) times the odds of AKI-D per 1-year increase. After adjustment for patient, cardiac procedure, and hospital characteristics, odds for developing AKI-D were only 1.01 times the previous year (95% CI, 0.99-1.02) and were no longer statistically significant (Table 2) . AKI-D incidence increased similarly in men and women and across age groups, though incidence was more variable by age (Figures 3 and 5) .
In-hospital mortality for postcardiac catheterization or PCI AKI-D patients decreased from 28. increase in yearly AKI-D incidence after cardiac catheterization or PCI (adjusted yearly OR=1.01; Table 2 ). The population-attributable risk of mortality associated with AKI-D after cardiac catheterization or PCI rose from 3.8% in 2001 to 6.5% in 2011. Median length of stay and proportion of patients discharged to skilled nursing facilities remained static across the study period. Figure 6 depicts the relatively unchanging median length of stay over time. Additionally, we calculated overall unweighted AKI and AKI-D rates for (1) Table 5 ). We observed similar trends to the overall study, confirming increased rates of both AKI and AKI-D among procedure subgroups for cardiac catheterization only, PCI only, and cardiac catheterization with PCI.
Discussion
Rates of AKI and AKI-D in this study population rose significantly between 2001 and 2011. AKI incidence increased 3-fold during the study period, whereas AKI-D incidence increased 2-fold. Although the proportion of AKI and AKI-D patients dying in-hospital decreased, both the absolute number of deaths and the population-attributable risk of death for AKI and AKI-D increased from 2001 to 2011. Over 40% of deaths after cardiac catheterization or PCI occur in combination with AKI, whereas 6.5% occur in combination with AKI-D. Based on these findings, a significant opportunity exists to prevent and manage AKI and AKI-D among cardiac catheterization and PCI patients in the United States.
Epidemiological investigations indicate that AKI and AKI-D incidence is increasing among hospitalized patients. 16, 17, 21, 22 Using the NIS, Hsu found that the odds of developing AKI-D increased by 10% annually among hospitalized patients in the Please note that we use survey methods with population weights and adjust for age, sex, race, congestive heart failure, pulmonary circulation disorders, peripheral vascular disease, hypertension, other neurological disorders, chronic pulmonary disease, diabetes without chronic complications, diabetes with chronic complications, renal failure, obesity, fluid and electrolyte disorders, blood loss anemia, deficiency anemias, sepsis, cardiac catheterization, yearly median length of stay, and the proportion of patients discharged to skilled nursing facilities. AKI indicates acute kidney injury; AKI-D, dialysisrequiring acute kidney injury; PCI, percutaneous coronary intervention. United States between 2000 and 2009. 17 Similarly, Lenihan and Khera utilized the NIS to investigate the temporal incidence of AKI and AKI-D, but among cardiac surgery and elderly PCI patients. 16, 22 Compared to 1999, the adjusted odds of AKI and AKI-D in 2008 for cardiac surgery patients were 3.30 and 2.23, respectively. 16 Among elderly PCI patients (≥75 years), the adjusted odds of AKI and AKI-D in 2010 compared to 2002 were 1.87 and 0.20, respectively. We found similar, though smaller, odds of AKI among cardiac catheterization and PCI patients from 2001 to 2011 using NIS discharge data. We expected slightly smaller odds of AKI in our cohort, compared to the Lenihan and Khera studies, because cardiac surgery and elderly PCI patients have an increased risk of AKI attributed to age and comorbidity burden. 16, 22 Unlike other studies, we found that cardiac catheterization and PCI patients did not have significantly different odds of AKI-D in 2011 versus 2001, despite the doubling of such cases over the study period. Not all studies show AKI and AKI-D increases in the United States. In an analysis of acute myocardial infarction patients across 56 health care centers, Amin found that AKI incidence declined from 27% to 20% from 2000 to 2008. 23 However, this study reported trends in hospital-based incidences for patients at experienced treatment centers, not all of which underwent coronary angiography. Nevertheless, these results highlight the importance of studying trends across different populations to identify modifiable risk factors to prevent AKI and AKI-D. 24 There are several possible explanations for our observed increase in AKI and AKI-D incidence between 2001 and 2011. Whereas PCI patient age distribution remained relatively constant, we did notice a trend toward increasing comorbidity burden over time, including specific AKI risk factors such as hypertension, obesity, and diabetes. However, adjusting for these risk factors only partially accounted for the observed growth. Another potential contributor is the increasing complexity of procedures being performed, whether attributed to the complexity of the procedures themselves or to increasingly complex settings. Improvements in sensitivity attributed to increasing provider awareness over time may have also partially explained the observed temporal increase in AKI incidence. [25] [26] [27] [28] [29] [30] Recently, Grams et al. demonstrated an increase in sensitivity of administrative codes for AKI from 10% to 24% over a similar time interval as our study with a high, constant specificity. 29, [31] [32] [33] Though this increase in code sensitivity likely accounts for some of the increase in AKI, research that uses consistent creatinine-based definitions for AKI over the duration of their studies (rather than administrative codes) has suggested that the increase in AKI incidence is real. 34 Such consistent definitions provide argument against a higher false-positive rate. Additionally, assuming 10% of AKI cases were coded correctly at the beginning of our study period and a constant populationbased incidence rate over time, an increase in sensitivity would also not explain the observed increase in AKI-D, which is a condition more tightly linked to billing with lower rates of misclassification.
Evidence also suggests that clinicians may be taking a more aggressive approach to dialysis. Siddiqui et al. found that median time to dialysis after major elective surgery decreased from 5 to 2 days, indicating that changing practice patterns may be playing a role. 35 Inclusion of additional 22 However, the raw number of patient deaths for this population increased more than 3-fold during the same time. 22 Our analysis shows similar findings. Despite a decrease in the odds of death among cardiac catheterization or PCI patients with AKI or AKI-D from 2001 to 2011, the population-attributable risk for mortality increased by 15.3% and 2.7%, respectively. The proportion of potentially preventable deaths associated with AKI and AKI-D among cardiac catheterization and PCI patients is on the rise. Our main strength is the use of a large, multiyear, nationally representative sample of cardiac catheterization and PCI patients in the United States. The advantages of using such a data set include increased statistical power, improved outcome estimation accuracy, and wider generalizability of results. In addition, our study was conducted on patients undergoing cardiac catheterization or PCI, procedures that are increasingly applied to patients at risk for AKI. Although some reports indicate a decline in PCI use, catheterization capacity in the United States continues to grow and the cumulative use of PCI and other types of cardiac catheterization is on the rise, as demonstrated in this analysis. 36, 37 Our study has a number of limitations. First, we used ICD-9-CM administrative billing codes to identify patients in our sample with a diagnosis of AKI or AKI-D, and the sensitivity of these codes has increased over time, which could exaggerate the increase in AKI incidence. 29 Clinical or laboratory data, such as serum creatinine, would have provided the most accurate indicator for renal dysfunction had it been available. 38 Given the known sensitivity limitations of administrative codes for AKI, our results may underestimate its true incidence. Another limitation to our study is that the NIS also does not provide granular detail about the underlying cause of AKI post-PCI. Though AKI is most frequently caused by ischemia and/or direct nephrotoxicity, there are many other causes that we were unable to distinguish in this study, such as medications, viruses, bacteria, systemic illnesses, extra-and intrarenal obstructions, cardiorenal syndrome, hepatorenal syndrome, systemic vasodilation, and volume depletion. 39 Unmeasured variation between in-and outpatient medical regimens may also have affected our results. Other factors, such as atheroembolic disease, may have contributed. In addition, the NIS database was limited in 2001 and may under-represent a national sample for that year; however, trends for AKI and AKI-D persist in subsequent years with larger samples.
It is also possible that we did not account for a potential underlying national decrease in in-hospital mortality, outside of cardiac catheterization and PCI. It is possible that such a trend would partially or wholly explain the decrease in mortality that we found, but identifying determinants of potential decreases in hospital mortality over time was beyond the scope of this work.
Additionally, because of the causal relationship between contrast media use and AKI, we assumed that cardiac catheterization or PCI temporally preceded AKI or AKI-D.
Finally, despite using the same data abstraction code for every year in the study period, there is a great deal of comorbidity information missing for 2001. We are unsure why this data are lacking.
Determining the incidence of, and mortality risk associated with, AKI and AKI-D among cardiac catheterization or PCI patients allows health care providers to understand the clinical significance of this adverse outcome. Although specific therapies for treatment of AKI are nonexistent, hospitals with cardiac catheterization capability should invest in implementing and standardizing prevention measures and avoiding further kidney damage to address mortality in this population. 6, 13, [40] [41] [42] [43] [44] [45] Moving forward, additional research is needed to examine differences in AKI and AKI-D incidence across additional cardiac catheterization or PCI patient subgroups, including geographical and socioeconomic subclasses. Our analysis demonstrates that incidence of AKI and AKI-D among cardiac catheterization or PCI patients increased drastically from 2001 to 2011. Over 40% of all deaths after cardiac catheterization or PCI occur in combination with AKI. Efforts to prevent AKI or AKI-D after cardiac catheterization or PCI would result in significant reductions in mortality risk for these patients.
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